Loyal
Veterinary drug company developing FDA-approved lifespan extension drugs for dogs.
22 of 403 companies
Veterinary drug company developing FDA-approved lifespan extension drugs for dogs.
Generative AI drug discovery company that tests candidates such as rentosertib against aging clocks.
Develops partial epigenetic reprogramming therapies using OSK factors, led by ER-100 for optic neuropathies.
Alphabet-founded company researching the biology of aging and developing drugs for age-related diseases.
Covalent small molecule discovery company working with Calico on targets for age-related diseases.
Uses human aging biology to develop cardiometabolic drugs, including the NLRP3 inhibitor BGE-102.
Partnered with Calico on aging drug research for over a decade before ending the alliance in 2025.
Developed senolytic drugs such as UBX1325 for eye disease; stockholders approved its dissolution in 2025.
Research company working on cellular rejuvenation programming to reverse disease.
Developed the IL-11 antibody 9MW3811, explored for age-related diseases and licensed to Calico.
Uses an AI virtual cell platform and aging clocks to find single-gene targets for safer cell rejuvenation.
Clinical-stage company developing drugs that target metabolic pathways that decline with age, such as AMPK and mTOR.
Formerly clock.bio; builds science and tools to measure and rejuvenate human cells and tissues.
Invested in NewLimit's 2025 extension round through Eli Lilly and Company.
Uses an in vivo drug discovery platform to find targets and therapies for complex age-related diseases.
Funds research, grants and company investments to extend healthy human lifespan.
Develops siRNA therapeutics that reset gene networks to reverse disease.
Develops medicines that target core aging mechanisms to treat and prevent age-related diseases.
Develops epigenetic reprogramming medicines to restore youthful function in old cells, starting with the liver.
Develops gene therapies for chronic age-related disease in companion animals and humans.
Develops autophagy drugs, iPSC-derived cell therapies and tissue reprogramming aimed at adding ten healthy years.
Develops drugs that target senescent cells, led by the topical GPX4 modulator RLS-1496.